Needle displacement during HDR brachytherapy in the treatment of prostate cancer.

PURPOSE We used clinical patient data to examine implant displacement between high dose rate (HDR) brachytherapy fractions for prostate cancer to determine its impact on treatment delivery. MATERIALS AND METHODS We analyzed the verification films taken prior to each fraction for 96 consecutive patients treated with HDR brachytherapy boosts as part of their radiation therapy for definitive treatment of organ-confined prostate cancer at our institution. Patients were treated with 18-24 Gy in 4 fractions of HDR delivered in 40 hours followed by 36-39.6 Gy external beam radiation to the prostate. We determined the mean and maximum displacement distances of marker seeds placed in the prostate and of the implanted needles between HDR fractions. RESULTS Mean and maximum displacement distances between fractions were documented up to 7.6 mm and 28.5 mm, respectively, for the implant needles and 3.6 mm and 11.4 mm, respectively, for the gold marker seeds. All displacement of implant needles occurred in the caudal direction. At least 1 cm caudal displacement of needles occurred prior to 15.5% all fractions. Manual adjustment of needles was required prior to 15% of fractions, and adjustment of the CLP only was required in 24%. Most of the displacement for both the marker seeds and needles occurred between the first and second fractions. CONCLUSIONS There is significant caudal displacement of interstitial implant needles between HDR fractions in our prostate cancer patients. Obtaining verification films and making adjustments in the treatment volume prior to each fraction is necessary to avoid significant inaccuracies in treatment delivery.

[1]  J. Cherlow,et al.  High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[2]  A. Shanberg,et al.  Management of prostate carcinoma. Combination of pelvic lymphadenectomy, temporary Ir-192 implantation, and external irradiation. , 1983, Radiology.

[3]  J. Blasko,et al.  Interstitial implantation techniques in prostate cancer , 1997, Journal of surgical oncology.

[4]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[5]  A. Shanberg,et al.  Followup prostate biopsy in patients with carcinoma of the prostate treated by 192iridium template irradiation plus supplemental external beam radiation. , 1992, The Journal of urology.

[6]  G. Gustafson,et al.  Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. , 1995, International journal of radiation oncology, biology, physics.

[7]  A. Shanberg,et al.  Temporary iridium‐192 implant in the management of carcinoma of the prostate , 1992, Cancer.

[8]  P. Unger,et al.  Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.

[9]  J. Blasko,et al.  Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[10]  S. Lannon,et al.  Long-term results of combined interstitial gold seed implantation plus external beam irradiation in localised carcinoma of the prostate. , 1993, British journal of urology.

[11]  T. Wheeler,et al.  Prostatic biopsy after irradiation therapy for prostatic cancer. , 1985, Urology.

[12]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[13]  Julie Dawson,et al.  Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants , 1994 .

[14]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[15]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Yan,et al.  Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.

[17]  B W Corn,et al.  Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. , 1997, International journal of radiation oncology, biology, physics.